Loading data for MLTX — first visit, this takes a few seconds.

MoonLake Immunotherapeutics (MLTX)

NasdaqCM: MLTX · 即時價格 · USD

14.94

-0.07 (-0.47%)

收盤價： Sep 11, 2026, 6:33 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	10.88
市值	1.08B
營收 (ttm)	n/a
淨利（ttm）	-264M
	1.03
	-3.84
	n/a
	-3.81
P/B (ttm)	2.48
P/S (ttm)	0.00
財報日期	Nov 5, 2026

賣價	18.99
成交量	1,464,821
20 日平均成交量	1,273,146
開盤價	14.80
前收盤價	15.01
當日區間	14.73 - 15.43
52 週範圍	5.95 - 62.75
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 MLTX

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was foun...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Oct 20, 2020

員工 130

證券交易所 NasdaqCM

股票代號 MLTX

網站 https://www.moonlaketx.com

完整的公司簡介

財務表現

MoonLake Immunotherapeutics 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -227.32M，較前期增加 91.13%。

財務報表

財報驚奇

MoonLake Immunotherapeutics 已於 Aug 10, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.84 超出預期 0.06, 年增 3.45% 成長.

下次財報發布

MoonLake Immunotherapeutics 的下次財報預計於 Nov 5, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

1 月前 · Stocktwits

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’

At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.

1 月前 · Stocktwits

MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data

MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis.

1 月前 · Zacks

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...